Hybrid proteins with ErbB4 extracellular domain and neuregulin heparin-binding domain for targeting
Polypeptides of the neuregulin (NRG) heparin binding domain (N-HBD) and nucleic acids coding therefor are disclosed. In particular, fusion polypeptides are produced that comprise, as a targeting structure, a N-HBD polypeptide, fragment, homologue or functional derivative and a protein to be targeted. This is fused to a polypeptide or peptide being targeted (P<SUB>trg</SUB>) to cell surfaces rich in heparan sulfate proteoglycans to either activate or inhibit interactions at tyrosine kinase receptors. A preferred fusion polypeptide comprises an N-HBD, a spacer and the extracellular domain of erbB4, one of several receptors signaled by NRG, which is potent NRG antagonist. Such products are used to treat diseases or conditions where either agonism or antagonism at tyrosine kinase receptors has beneficial effects, including cancer and a multitude of diseases of the nervous system.
1. A fusion polypeptide comprising
(a) a targeting polypeptide that comprises a human neuregulin heparin binding domain (N-HBD); and
(b) fused directly C-terminally to the N-HBD, a peptide linker or spacer (S) that is the natural amino acid spacer of human neuregulin, the sequence of which is residues 131-195 of SEQ ID NO: 14, and
(c) fused directly C-terminally to S, a targeted polypeptide that comprises human erbB4 receptor extracellular domain (B4-ECD) that is to be targeted and localized to the heparan sulfate-rich cell or tissue surface;
wherein
(i) said fusion polypeptide binds heparan sulfate when said fusion polypeptide is permitted to contact cells or tissues, thereby localizing the B4-ECD of (c) to heparan sulfate-rich cell or tissue surface; and
(ii) said fusion polypeptide has enhanced biological activity in blocking a target receptor compared to native human B4-ECD or human B4-ECD that is not fused to said S and said human N-HBD.
2. The fusion polypeptide of claim 1 further comprising a tag sequence.
3. The fusion polypeptide of claim 2 wherein the tag sequence is a C-terminal influenza hemagglutinin (HA) sequence.
4. The fusion polypeptide of claim 1 the sequence of which is SEQ ID NO: 14, in which the N-HBD is residues 31-130 and B4-ECD is residues 200-820.
5. A pharmaceutical composition useful for delivering a B4-ECD to a cell or tissue surface and enhancing the biological activity of the B4-ECD, comprising:
(a) the fusion polypeptide of claim 1 ; and
(b) a pharmaceutically acceptable excipient or carrier.
6. A pharmaceutical composition useful for delivering a B4-ECD to a cell or tissue surface and enhancing the biological activity of the B4-ECD, comprising:
(a) the fusion polypeptide of claim 4 ; and
(b) a pharmaceutically acceptable excipient or carrier.
7. A method of inhibiting the activation by neuregulin of an EGF-receptor and/or inhibiting the stimulation of the growth of cells bearing such receptor by neuregulin, comprising providing to said receptor or cells an effective amount of the fusion polypeptide of claim 1 , that inhibits binding of neuregulin and activation of said receptor.
8. A method of inhibiting the activation by neuregulin of an EGF-receptor and/or inhibiting the stimulation of the growth of cells bearing such receptor by neuregulin, comprising providing to said receptor or cells an effective amount of the fusion polypeptide of claim 4 , that inhibits binding of neuregulin and activation of said receptor.
9. A method for treating a tumor or cancer in a subject in which tumor growth and/or metastasis is dependent upon autocrine neuregulin signaling, comprising administering to said subject an effective amount of the pharmaceutical composition of claim 5 ,
wherein the biological activity of the B4-ECD of the fusion polypeptide is increased compared to the activity of native B4 ECD or a B4 ECD not fused to said S and said human N-HBD,
thereby treating said tumor or cancer.
10. The method of claim 9 wherein said tumor or cancer is a breast or ovarian tumor or cancer.
11. A method for treating a tumor or cancer in a subject in which tumor growth and/or metastasis is dependent upon autocrine neuregulin signaling, comprising administering to said subject an effective amount of the pharmaceutical composition of claim 6 ,
wherein the biological activity of the B4-ECD of the fusion polypeptide is increased compared to the activity of native B4 ECD or a B4 ECD not fused to said S and said human N-HBD,
thereby treating said tumor or cancer.
12. The method of claim 11 , wherein said tumor or cancer is a breast or ovarian tumor or cancer.